Cover Image

Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart

New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better...

Full description

Saved in:
Bibliographic Details
Main Authors: Ghigo, Alessandra (Author) , Ameri, Pietro (Author) , Asnani, Aarti (Author) , Bertero, Edoardo (Author) , de Boer, Rudolf A. (Author) , Farmakis, Dimitrios (Author) , González, Arantxa (Author) , Heymans, Stephane (Author) , Ibáñez, Borja (Author) , López-Fernández, Teresa (Author) , Lyon, Alexander R. (Author) , Pollesello, Piero (Author) , Rakisheva, Amina (Author) , Stellos, Konstantinos (Author) , Streckfuss-Bömeke, Katrin (Author) , Tocchetti, Carlo Gabriele (Author) , Thum, Thomas (Author) , van der Meer, Peter (Author) , Van Rooij, Eva (Author) , Ponikowski, Piotr (Author) , Metra, Marco (Author) , Rosano, Giuseppe (Author) , Van Linthout, Sophie (Author)
Format: Article (Journal)
Language:English
Published: June 2025
In: European journal of heart failure
Year: 2025, Volume: 27, Issue: 6, Pages: 1028-1046
ISSN:1879-0844
DOI:10.1002/ejhf.3636
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ejhf.3636
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.3636
Get full text
Author Notes:Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López-Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss-Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, and Sophie Van Linthout
Description
Summary:New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in vitro two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.
Item Description:Online veröffentlicht: 11. März 2025
Gesehen am 21.07.2025
Physical Description:Online Resource
ISSN:1879-0844
DOI:10.1002/ejhf.3636

Similar Items